NCT01067287 2026-04-06
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Beth Israel Deaconess Medical Center
Phase 2 Completed
Clinical Trials
12 trialsNCT02077959 2023-01-27
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT01313416 2019-07-10
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Augusta University
Phase 2 Terminated
NCT01420965 2019-07-10
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
Phase 2 Terminated
NCT02530125 2018-03-19
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Northwestern University
Phase 2 Terminated
NCT01386502 2017-07-02
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01441765 2017-02-08
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00904722 2016-06-03
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01435369 2016-01-21
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Medivation, Inc.
Phase 2 Completed
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00532259 2014-09-12
CT-011 MAb in DLBCL Patients Following ASCT
CureTech Ltd
Phase 2 Completed
NCT00966251 2012-10-23
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
CureTech Ltd
Phase 1/2 Terminated